A small population of stem cell-like precursors in solid tumors are linked to histological composition, progression, angiogenesis, metastasis, recurrence and drug resistance of a variety of malignant tumors. Oligoastrocytoma is the most common brain mixed glioma composed of mixed cells of oligodendroglial and astrocytic phenotypes. Identification and characterization of stem cell-like precursors in oligoastrocytoma may shed light on the oncogenesis of this unique type of tumor and assist in the design of novel therapeutic strategy. Here, tumor stem cell-like precursors were identified from primary human anaplastic oligoastrocytomas by labeling of the tumor sections with nestin and CD133. Tumor cells were cultured in vitro in stem cell medium with growth factors and the capacity of the surviving stem cell-like precursors to form tumor spheres was tested. The tumor spheres were further injected subcutaneously into nude mice to observe the contribution of stem cell-like precursors to histological composition and tumor progression. We found that primary human oligoastrocytoma tissues contained nestin þ /CD133 þ stem cell-like precursors. These cells differentiated into tumor cells with both oligodendroglial and astrocytic characteristics and formed tumor spheres in vitro, which upon implantation in nude mice, grew into tumor nodules containing nestin þ /CD133 þ cells at levels higher than in the primary tumor tissues. This study revealed for the first time that anaplastic human oligoastrocytomas contained stem cell-like precursors, which exhibit neural stem cell properties with tumorigenicity. These stem cell-like precursors may be responsible for the oligodendroglial and astrocytic components of human oligoastrocytoma and should be considered as therapeutic targets.
The theory of tumor stem cells (TSCs), or cancer stem cells, implies that, similar to normal tissues, malignant tumors might also 'develop' from somatic stem cells that accumulated mutations leading to transformation. 1 Although this theory met skepticism, over the past decade there has been abundant evidence to support the role of embryonic and fetal stem cells in oncogenesis. 2 It has been found that mutations occurring during expansion phases of totipotential stem cells throughout development may prompt the formation of tumors in adulthood. In mature adult tissues, stem cells and progenitor cells may also constitute the sources of oncogenic transformation following somatic mutations, as shown by the isolation of TSCs from human acute myeloid leukemia (AML) [3] [4] [5] [6] and breast cancer. [7] [8] [9] In tumors of the central nervous system (CNS), TSCs have also been isolated and successfully maintained in culture from medulloblastoma, 10 glioblastoma, [11] [12] [13] [14] [15] [16] [17] [18] and ependymoma, 19 as well as from several glioma cell lines. 17, 20 These results suggest that brain tumors may contain a subpopulation of precursor cells that share similar surface markers and properties with neural stem cells. Oligoastrocytoma is a CNS tumor type composed of a mixture of cells of astrocytic and oligodendrocytic origin. Since this tumor type is second only to astrocytomas in the rate of incidence among CNS tumors 21 and is often lethal, it is important to investigate the existence of TSCs so as to gain insight into tumor development, progression and the cause for mixed histological pattern. In this study, we report the isolation of tumor-stem cell like precursors from human primary oligoastrocytoma tissues and characterization of the contribution of such precursor cells to the unique tumor histology and progression.
Materials and methods

Culture of Tumor Spheres from Primary Human Oligoastrocytoma Tissues
Tumor tissues from three cases of anaplastic oligoastrocytoma were obtained with the informed consent of the patients as approved by the institutional Research Ethics Board at Southwest Hospital, Chongqing, China, PR. Tumor tissues were used for primary cell culture and immunohistochemical staining. For primary tumor cell culture, the tissues were cut into 1 Â 1 Â 1 mm 3 pieces and cultured in 50-mm 2 flasks in 0.5 ml fetal calf serum (FCS). After 4 h, the flasks were replenished with 3 ml DMEM (Gibco, USA) containing 10% FCS. When a monolayer of primary tumor cells was formed, the cells were detached with 0.25% trypsin (Gibco) and suspended in defined stem cell medium, that is, DMEM/F12 (Gibco) containing 20 ng/ml basic fibroblast growth factor (bFGF, Peprotech, USA), 20 ng/ ml epidermal growth factor (EGF, Peprotech), B27 Supplement (1 Â , Gibco), 2 mmol/l L-glutamine and 4 U/l insulin. The culture media were replaced every 4 days. When the primary neurospheres were passed, we dissociated and plated the cells from the neurospheres in 96-well plates at a density of 10 cells/well in 0.2 ml of the defined stem cell medium to acquire the secondary neurospheres.
Immunocytochemistry of Tumor Spheres
The spheres formed by primary tumor cells were placed onto coverslips precoated with poly-L-lysine (Sigma, USA) in DMEM containing 10% FCS. The spheres were fixed with 4% paraformaldehyde for 20 min at room temperature, treated with normal goat serum (Boshide Biotech, China) and then were incubated with the following antibodies: rabbit antihuman nestin polyclonal antibody (1:100 dilution, Chemicon, USA) and mouse anti-human CD133/1 monoclonal antibody (1:50 dilution, Milteny Biotech, Germany). The primary antibodies bound on tumor cells were reacted with FITC-conjugated goat anti-rabbit or anti-mouse IgG (1:50, Sigma). The cells were then counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI, 100 mg/ml, Sigma) or propidium iodide (PI, 5 mg/ml, Sigma) to reveal the nuclei.
For testing the differentiation potential of the neurospheres formed by the TSCs, the secondary tumor spheres were seeded onto coverslips in DMEM containing 10% FCS. The differentiation markers including glial fibrillary acidic protein (GFAP) for astrocytes and myelin basic protein (MBP) for oligodendrocytes as well as CD133 for stem cells were detected by immunocytochemistry on the coverslips with the spheres. Briefly, the cells were fixed with 4% paraformaldehyde for 20 min at room temperature, treated with normal goat serum and then stained with the following antibodies: rabbit anti-human GFAP polyclonal antibody (1:100 dilution, Zhongshan Jinqiao Biotech, China), rabbit anti-human MBP polyclonal antibody (1:200 dilution, Boshide Biotech, China). The primary antibodies were bound by TRITC-conjugated goat anti-rabbit IgG (1:100, Sigma) and FITC-conjugated goat anti-rabbit IgG (1:50, Sigma) respectively. The cells were counterstained with DAPI to reveal the nuclei.
Implantation of Tumor Spheres in Nude Mice
To evaluate the in vivo tumorigenicity of CD133 À differentiated tumor cells respectively (5 Â 10 3 and 5 Â 10 4 per mouse, five mice for each group) in 100 ml of serumfree DMEM/F12 in the right chest. Tumor volume (T V ) was calculated by using the following formula: T V (tumor volume) ¼ l (length) Â w 2 (width)/2. At the tenth week after implantation, the mice were killed and tumors were removed for histological examination and immunohistochemistry for CD133, nestin, GFAP and MBP. Mice were hosted according to the guidelines of the institutional Committee for Laboratory Animal Usages.
Immunohistochemical Staining of Tumor Tissues
For examination of TSCs in tumor tissues, nestin and CD133 were detected with immunofluorescence on cryostat sections. The specimens from either human specimens or nude mice were fixed in 4% paraformaldehyde, embedded in Tissue-Tek OCT (optimal cutting temperature) compound and frozen at À201C for cryostat sections (8 mm), which were mounted on poly-L-lysine-coated slides, and airdried for 24 h. The sections were pretreated with normal goat serum for 30 min at 371C and then incubated with primary antibody (rabbit anti-human nestin or mouse anti-human CD133 antibody) overnight, followed by incubation with FITC-or TRITCconjugated secondary antibody (goat anti-rabbit or anti-mouse IgG). For double labeling of nestin and CD133 on the sections, both the primary antibodies were used overnight, and both TRITC-conjugated goat anti-rabbit IgG and FITC-conjugated IgG were used as secondary antibodies. The sections were counterstained with DAPI to reveal the nuclei. The stained sections were examined and photographed with a laser confocal scanning microscope (Leica, Germany).
To detect GFAP and MBP, two differentiation markers for the tumor cells, in the tumor tissues, paraffin-embedded sections were used for immunohistochemistry. The tumor tissues were fixed in 10% phosphate-buffered formalin and embedded in paraffin for sectioning. The tumor sections were incubated with rabbit anti-human GFAP or antihuman MBP polyclonal antibody, followed by detection using the ChemMate Detection kit (Dako). A positive reaction was indicated by brown color using DAB, and was counterstained with hematoxylin.
Cells positive for GFAP, MBP or CD133 were quantified by counting all stained cells within 20 randomly selected microscopic fields, and the percentages were calculated on the basis of the total number of nuclei counted.
Statistical Analysis
Parametric data were expressed as the mean values7standard deviation (s.d.). Data were analyzed with computer aided SPSS10.0 statistical software. When two groups were compared, the unpaired dependent-samples t-test was used. A value of Po0.05 was considered statistically significant.
Results
Histopathology and Immunohistochemistry of Primary Human Tumor Tissues
All three cases of anaplastic oligoastrocytoma were located in the cerebral hemispheres, compressing the ventricles (Figure 1a-c) . The tumor tissues used for primary culture had typical histologic features of anaplastic oligoastrocytomas. Immunostaining showed various numbers of GFAP-positive tumor cells mixed with MBP-positive tumor cells, representing two types of distinctly differentiated tumor cells (Figure 1d-f) . To identify the stem cell-like precursors, or TSCs, we used either single or double immunofluorescence staining with antibodies to nestin and CD133. We found a few tumor cells positive for nestin in the cytoplasm or CD133 on the cell membrane (Figure 2a-j) .
Formation of Tumor Spheres
Dissociated primary tumor cells were seeded for 24 h in serum-free medium supplemented with EGF and bFGF. Most of the tumor cells became adherent, with a minority of floating cells forming spheres composed of two to three cells. After an additional 48 h, the floating spheres were expanded to contain 10-20 tumor cells, with bright appearance and a sharp edge. On the sixth day, the spheres further expanded, with cell numbers in each sphere ranging from 100 to 200 (Figure 3a-c) . The center of the 
Phenotype of Tumor Spheres
We stained tumor cells in the spheres with immunofluorescence of neural stem cell markers CD133 and nestin. Tumor cells in the spheres expressed both CD133 and nestin (Figure 3d 
Tumorigenicity of Tumor Spheres
Tumor spheres were transplanted s.c. to nude mice and tumor nodules were palpable after 9 weeks in mice implanted with 5 Â 10 4 CD133 þ /nestin þ cells. 
Discussion
In the 1970s, cancer cells derived from a single tumor showed different ability to form clones in vitro. This has led to the vigorous studies of the presence of stem-like cells that may constitute the origin of malignant tumors. In fact, 'tumor stem cells' have been isolated from a variety of malignant human solid tumors. As compared with committed tumor cells, stem-like tumor cells not only possess the property of self-renewal and multipotent differentiation, but also are more pro-angiogenic and resistant to radio-or drug therapy. [22] [23] [24] Tumor stem cells are considered as the origin of the initiation, progression, metastasis and recurrence of malignant tumors. [25] [26] [27] Thus far, brain tumor stem cells have been isolated from malignant fetal neuroepithelial tumors or glioblastoma multiforme. Our study further provides evidence for the existence of stem cell-like precursors in human oligoastrocytoma, with the expression of nestin and CD133, two key markers of neural stem cells.
We found that tumor spheres formed by cells from oligoastrocytomas expressed CD133 and nestin, and the cells derived from these tumor spheres possessed the properties of stem cells. However, these CD133 À cells may not represent bona fide glioblastoma stem cells. We therefore further studied the function of these CD133 þ cells. Secondary spheres were acquired from diluted cloning, indicating that these cells possessed the property of self-renewal. CD133 þ sphere cells negative for either GFAP or MBP could differentiate into adhesive cells positive for GFAP or MBP, suggesting their property of multilineage differentiation. Additionally, the sphere cells were tumorigenic when implanted in nude mice, therefore, CD133 þ cells isolated from human oligoastrocytoma cells exhibited characteristics of stem cells.
As a common malignancy in the brain, oligoastrocytoma is positive both for the oligodendroglial marker MBP and the astrocytic marker GFAP. In our study, the primary human tumors were diagnosed as anaplastic oligoastrocytomas (WHO grade III), which were both MBP and GFAP positive. The tumors contained dispersed nestin-and CD133-positive cells, which have been thought to be the origin of oligoastroglioma. 21 Based on the 'double lineage' theory, committed oligodendrocytes and type II astrocytes are progeny derived from As the result of transformation of O 2 A progenitors or their parental generation, it appears reasonable to explain why the rate of oligoastrocytomas is rather frequent in mixed gliomas, consistent with the interpretation of the origin of tumors by 'cancer stem cell' hypothesis. Self-renewal and differentiation are basic properties of stem cells. 28 When cultured in serum-free medium, committed tumor cells usually cease propagation, whereas tumor stem cells continue to proliferate. We found that tumor cells in the spheres formed by primary oligoastrocytoma stem cell-like precursors expressed both nestin and CD133. When recultured in medium containing FCS, tumor spheres became adherent and their progeny cells resembled the primary tumor cells. In order to distinguish stem cell-like precursors isolated from oligoastrocytoma from normal neural stem cells, we implanted tumor spheres formed by stem cell-like precursors into nude mice. The xenograft tumors showed a latent time much longer than the conventional xenografts, 29 implying the tumorigenicity of these stem cell-like precursors and their potential to act as the source of tumor recurrence during therapy. Thus, our successful isolation and characterization of stem-like cells will provide further insight into the understanding of the development and progression of human anaplastic oligoastrocytoma and assist in the design of more effective therapeutic means for this lethal tumor in the brain.
